Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Clinical Analysis of 107 NSCLC Patients Harboring KRAS Mutation].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 May 2016

Zhang Quan, Wang Jinghui, Li Xi, Zhang Hui, Nong Jingying, Qin Na, Zhang Xinyong, Wu Yuhua, Yang Xinjie, Lv Jalin, Zhang Shucai

Abstract excerpt

BACKGROUND: Kirsten rat sarcoma viral oncogene (KRAS) mutation is one of the major driver genes of non-small cell lung cancer (NSCLC). KRAS is a resistant predictor of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which raises controversy because of its role in chemotherapy sensitivity and prognosis. The aim of this study is to accumulate clinical experience in treating NSCLC patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 27215453
DOI: 10.3779/j.issn.1009-3419.2016.05.02
PMCID: PMC5973060

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Clinical Analysis of 107 NSCLC Patients Harboring KRAS Mutation].PMID 27215453Read ↗

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].Semantic proximity Read ↗

First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.Semantic proximity Read ↗

Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.Semantic proximity Read ↗

[EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance].Semantic proximity Read ↗

KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies.Semantic proximity Read ↗

[A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib].Semantic proximity Read ↗

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung CancerSemantic proximity Read ↗

KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.Semantic proximity Read ↗

[Current status and outlook of medical treatment for KRAS-mutated non-small cell lung cancer].Semantic proximity Read ↗

The KRAS G12C mutation in NSCLC: from target to resistanceSemantic proximity Read ↗

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.